Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Lixte Biotechnology Holdings, Inc. LIXTW NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
28/100
0/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Lixte Biotechnology Holdings, Inc. (LIXTW) is a Biotechnology company in the Healthcare sector, currently trading at $0.02. It has a SharesGrow Score of 25/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $6.1B (loss), growing at -56453.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $1.0B against $9.7B equity (Debt-to-Equity (D/E) ratio 0.11, conservative). Current ratio is 3.88 (strong liquidity). Debt-to-assets is 8.1%. Total assets: $12.7B.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

LIXTW SharesGrow Score Overview

37/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — LIXTW

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
LIXTW: +0%/yr revenue is, -56453.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet LIXTW: Debt-to-Equity (D/E) ratio 0.11 (conservative), Current ratio is 3.88 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
LIXTW: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.01-0.38
Volume1.17K
Avg Volume (30D)24.05K
Market Cap$100.55K
Beta (1Y)0.89
Share Statistics
EPS (TTM)-1.26
Shares Outstanding$48.41M
IPO Date2020-11-27
Employees2
CEOGeordan G. Pursglove
Financial Highlights & Ratios
EBITDA$-5.11B
Net Income$-6.08B
Operating Income$-5.11B
Total Cash$5.11B
Total Debt$1.03B
Net Debt$-4.07B
Total Assets$12.73B
Price / Earnings (P/E)-0
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS5393191110

Price Chart

Track all markets on TradingView
LIXTW
Lixte Biotechnology Holdings, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.01 52WK RANGE 0.38

People Also View

ATNFW
ATNFW
CannBioRx Life Sciences Corp.
$0.43
-6.52%
 RVPHW
RVPHW
Reviva Pharmaceuticals Holdings, Inc.
$0.00
-16.67%
 ARTLW
ARTLW
Artelo Biosciences, Inc.
$0.01
+0.00%
 BCDAW
BCDAW
BioCardia, Inc.
$0.01
-3.17%
 ENTXW
ENTXW
Entera Bio Ltd. WT EXP 062723
$0.00
-60.00%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message